WO2015028035A1 - Composition dermatologique - Google Patents

Composition dermatologique Download PDF

Info

Publication number
WO2015028035A1
WO2015028035A1 PCT/DK2014/050265 DK2014050265W WO2015028035A1 WO 2015028035 A1 WO2015028035 A1 WO 2015028035A1 DK 2014050265 W DK2014050265 W DK 2014050265W WO 2015028035 A1 WO2015028035 A1 WO 2015028035A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
kigelia
composition
treatment
prevention
Prior art date
Application number
PCT/DK2014/050265
Other languages
English (en)
Inventor
Flemming Licht
Original Assignee
Unigroup Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unigroup Aps filed Critical Unigroup Aps
Priority to EP14776569.7A priority Critical patent/EP3041460A1/fr
Publication of WO2015028035A1 publication Critical patent/WO2015028035A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives

Definitions

  • the present invention relates to a composition comprising ethyl lactate and kigelia.
  • a dermatological composition for the treatment of dermatitis such as diaper dermatitis and/or imperfections of the skin, such as acne, pimples and folliculitis.
  • the patent GB 1388836 describes a composition for treating skin, in particular acne, which composition comprises ethyl lactate (lactic acid ethyl ester). According to this patent, the composition should be water-free to prevent hydrolysis of the ester.
  • the patent GB 1555796 describes a composition for treating skin, in particular acne, which composition comprises ethyl lactate. According to this patent, it is necessary to employ water in the composition to ensure that the skin does not become excessively dehydrated. Ethyl lactate is stabilized in the presence of water using a buffer to control the pH.
  • the patent US 4613592 describes a water-in-oil emulsion for topical application to human skin for the treatment of acne, particularly a water-in-oil cream containing ethyl lactate.
  • the emulsion comprises a silicone oil ingredient and an emulsifier, in addition to a buffer.
  • a fluid lotion tends to flow away from acne lesions, and there exists consumer reluctance to accept that a clear liquid possesses curative active ingredients.
  • Folliculitis also known as "Hot Tub Rash" is the inflammation of one or more hair follicles.
  • the condition may occur anywhere on the skin with the exception of the palms of the hands and soles of the feet.
  • Diaper dermatitis is one of the most common skin disorders of infants and children. The reported incidence and age of onset vary worldwide, related to differences in diaper use, toilet training, hygiene, and child-rearing practices in different countries (Singalavanija S, Frieden IJ. Diaper dermatitis. Pediatr Rev 1995; 16:142. Levy M. Diaper rash syndrome or dermatitis. Cutis 2001; 67:37. Ward DB, Fleischer AB Jr, Feldman SR, Krowchuk DP. Characterization of diaper dermatitis in the United States. Arch Pediatr Adolesc Med 2000; 154:943. Scheinfeld N. Diaper dermatitis: a review and brief survey of eruptions of the diaper area. Am J Clin Dermatol 2005; 6:273).
  • irritant dermatitis in a broad sense represents response to the physical or toxic effects of a wide range of environmental exposures. Dermatitis arises when the defense or repairing capacity of the skin is exhausted, or when the penetration of chemicals excites an inflammatory response. The three main factors involved in the pathogeneses of irritant dermatitis are, disturbed barrier function, epidermal cell change and release of inflammatory mediators and cytokines (Wilkinson SM, Back MH .Contact dermatitis: Irritant in: Burns T, Breathnach S, Cox N, Griffiths S C; editors. Rooks Text Book of Dermatology, 7th edition; Blackwell Science, Oxford 2004 : pl9.1, 19.3, 19.18). In diaper dermatitis , factors like moisture, friction, urine, feces, and sometimes micro organism, result in dermatitis. The barrier function of the skin is affected, which results in an increase in irritant chemical penetration and pathogen replication (Boiko
  • a topical composition comprising kigelia and one or more C1-C4 alkyl esters of lactic acid, malic acid, tartartic acid or citric acid.
  • composition preferably a topical composition, comprising ethyl lactate and kigelia.
  • ethyl lactate may counteract keratinisation.
  • the primary symptom of acne is a disorder in the keratinasation of the upper part of the pilosebaceous follicle.
  • the follicular ostium becomes obstructed by hyperkeratinised and cohesive horny cells.
  • ethyl lactate may arrest hyperkeratinisation.
  • a buffer which is suitable for topical such as skin application, such as for the treatment of acne or diaper dermatitis.
  • kigelia is a genus of flowering plants in the family Bignoniaceae. The genus comprises only one species, Kigelia africana.
  • Kigelia will be used to refer to the fruit extract of Kigelia africana.
  • Kigelia is used as a buffer. Kigelia may stabilize the composition at pH about 5.5, which appears to be a preferred value for the skin. It is proposed that kigelia is particularly suitable for stabilizing the pH in a composition according to the invention. Note that the pH may be lowered slightly in the presence of a citric acid buffer. Further, kigelia appears to have antibacterial, anti-inflammatory and analgesic properties, which may be desirable in a composition according to the invention.
  • kigelia is used as a preservative or a stabilizer of ethyl lactate.
  • Ethyl lactate is subject to be broken down by the sun light. This is in particular a problem upon using ethyl lactate in a composition for skin treatment, such as acne treatment, as the composition may be administered topically in a thin layer, exposing the external surface to sun light and humidity, and the internal surface to humidity or water emerging from the skin.
  • kigelia is an effective stabilizer of ethyl lactate subjected to sun light and humidity.
  • kigelia may act as an antioxidant. Antioxidant properties of kigelia are usually attributed to the contents of steroidic saponoside.
  • kigelia is derived from a natural source, which is likely to lead to acceptance to consumers.
  • kigelia is particularly suitable for a composition according to the present invention, combining buffer effect, antioxidant properties and preservative properties.
  • a patch comprising a composition according to the invention.
  • a patch is useful for keeping the composition in the intended place.
  • a discrete patch may conceal acne.
  • a patch may protect ethyl lactate from degradation from sun light, humidity or water.
  • a pen or stick comprising a composition according to the invention.
  • a pen or stick is particularly useful for the precise application of a composition of the invention.
  • kigelia as a pH stabilizer for a skin product, preferably for application to the face.
  • kigelia as a preservative, preferably for ethyl lactate.
  • Ethyl lactate may improve the penetration of the active ingredient.
  • the invention concerns a use of kigelia against Propionibacterium acnes (P. acnes).
  • composition comprising ethyl lactate and kigelia for the prevention or treatment of imperfections of the skin, comprising, but no limited to, acne and pimples.
  • the invention concerns a use of ethyl lactate for the prevention or treatment of dermatitis, such as diaper dermatitis.
  • Diaper dermatitis may be associated with increased pH, caused by bacteria breaking down urea to ammonia. By lowering the pH, the ammonia production may be inhibited.
  • the inventor of the present invention speculates that by adjusting the pH of the skin, symptoms of diaper dermatitis are alleviated or prevented.
  • the invention concerns a composition of the invention, for the prevention or treatment of diaper dermatitis.
  • the invention concerns a topical composition
  • kigelia comprising kigelia and one or more C1-C4 alkyl esters of lactic acid, malic acid, tartartic acid or citric acid.
  • Suitable C1-C4 alkyi esters comprise the methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl esters.
  • the esters of the polybasic acids malic acid, citric acid and tartaric acid the C1-C4 alkyi groups contained in the ester groups can be the same or different.
  • all carboxylic groups or only a part of the carboxylic groups can be esterified.
  • the corresponding malic acid and tartaric acid mono alkyi esters are considered in addition to malic acid and tartaric acid di-Cl-C4 alkyi esters.
  • the corresponding mono-, di- and tri-alkyl esters are suitable.
  • Preferred esters are the ethyl esters.
  • Further preferred esters are the isopropyl esters.
  • a preferred single compound is lactic acid ethyl ester.
  • Further preferred single compounds are malic acid diethylester and malic acid di-isopropylester.
  • C1-C4 alkyi lactates are suitable.
  • Particularly suitable C1-C4 alkyi lactates comprise, but are not limited to, ethyl lactate, n-propyl lactate, iso-propyl lactate, n-butyl lactate, iso-butyl lactate and tert-butyl lactate, and mixtures thereof.
  • the invention concerns a composition, comprising kigelia and an ethyl ester of lactic acid, malic acid, tartaric acid or citric acid.
  • the invention concerns a composition
  • a composition comprising kigelia together with lactic acid ethyl ester and/or malic acid diisopropylester
  • the invention concerns a topical composition
  • a topical composition comprising ethyl lactate and kigelia.
  • the invention concerns a composition for application to the skin.
  • the invention concerns a composition, for the prevention or treatment of Acne.
  • the invention concerns a composition, comprising a total amount of C1-C4 alkyi ester of lactic acid, malic acid, tartartic acid and/or citric acid selected among 1-80%, 2-50%, 3-40%, 5-30%, 10-25% and 15-20%.
  • the invention concerns a composition, comprising an amount of ethyl lactate selected among 1-80%, 2-50%, 3-40%, 5-30%, 10-25% and 15-20%.
  • the invention concerns a composition, comprising an amount of kigelia selected among 1-60%, 2-50%, 3-40%, 5-30%, 10-25% and 15-20%.
  • the invention concerns a composition, which is a solid at room temperature.
  • a solid composition is particularly useful for a stick.
  • the solid composition may preferably be provided as a powder.
  • the powder may exhibit a buffer effect upon contact with the skin of a user.
  • the invention concerns a composition, comprising an amount of alcohol, preferably ethanol, selected among 1-80%, 2-50%, 3-40%, 5-30%, 10-25% and 15-20%.
  • the invention concerns a composition, comprising an amount of water selected among 1-90%, 2-50%, 3-40%, 5-30%, 10-25% and 15-20%. The presence of water may be used for a lotion.
  • the invention concerns a composition, comprising an antioxidant, preferably a vitamin selected among vitamin E and vitamin C, more preferred vitamin C.
  • the invention concerns a composition, comprising an amount of vitamin selected among 0.1-60%, 0.2-50%, 0.3-40%, 1-30%, 2-20% and 5-10%.
  • the invention concerns a composition, further comprising a preservative and/or a moisturizer.
  • the invention concerns a composition, in form of a liquid, a lotion, an ointment, or a cream.
  • the invention concerns a patch comprising a composition according to the invention.
  • a patch is useful for keeping the composition in the intended place.
  • a discrete patch may conceal acne upon application.
  • a patch may protect ethyl lactate from degradation from sun light, humidity or water.
  • the invention concerns a patch, wherein said patch is a hydrocoiloid patch.
  • a hydrocoiloid plaster may act as a moisturizer. This allows administering ethyl lactate in the absence of water, potentially degrading ethyl lactate, without dehydrating the skin. Thus, a storage stable product is provided.
  • a hydrocoiloid plaster acts as a moisturizer.
  • the hydrocoiloid patch does not require the presence of a buffer, due to the absence of water in the composition.
  • the invention concerns a pen or stick comprising a composition according to the invention.
  • a pen or stick is particularly useful for the precise application of a composition of the invention.
  • the invention concerns a use of kigelia as a pH stabilizer, in particular providing stability against photodegradation.
  • the invention concerns a use of kigelia as a pH stabilizer for a skin product, preferably for application to the face.
  • the invention concerns a use of kigelia as a preservative, preferably for ethyl lactate.
  • the invention concerns a use of kigelia against Proplonibacterium acnes (P. acnes). According to an embodiment, the invention concerns a use of a composition comprising ethyl lactate and kigelia for the prevention or treatment of acne.
  • the invention concerns a use of a composition comprising ethyl lactate and kigelia for the prevention or treatment of folliculitis.
  • the invention concerns a composition of the invention, for the prevention or treatment of diaper dermatitis.
  • the invention concerns a use of ethyl lactate for the prevention or treatment of diaper dermatitis.
  • composition according to the invention may be made with the ingredients listed in Table I, Example A. Kigelia africana fruit extract dissolved in water.
  • the aim of this set of experiments was to test whether the use of Kigelia africana fruit extract increases the stability against degradation.
  • K. africana extract increases the stability against photodegradation, as well as provides improved storage stability.
  • citric-citrate buffer In order to prepare 100 mL of citric-citrate buffer, 23,25 mL of 0,02 M citric acid and 76,75 mL of trisodium citrate is mixed. In order to prepare 100 mL of citric-phosphate buffer, 43,125 mL of 0,02 M citric acid and 56,875 mL of sodium phosphate, dibasic is mixed. The pH of the buffers is adjusted with triethanolamine.
  • the oven is preheated to 50°C.
  • the oven should stay at this temperature during all of the experiment.
  • three samples of each formulation are used and their pH is measured every day, three times a day.
  • the compositions are the same as above.
  • a composition for a spray is prepared by mixing ethyl lactate, kigelia oil, canola oil, sweet almond oil, Cll-13 isoparaffin, vitamin E, borage oil, squalane, and C12-15 alkyl benzoate.
  • TEWL trans epidermal water loss
  • Fig. 1 shows a photo-oxidation study. The figure shows how kigelia stabilizes the pH better than the comparison examples, with buffers of citric-citrate and citric-phosphate.
  • Fig. 2 shows a chemical oxidation study indicating the storage stability of the samples.
  • the figure shows how kigelia stabilizes the pH better than the comparison examples, with buffers of citric- citrate and citric-phosphate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition contenant du lactate d'éthyle et du Kigelia. L'invention concerne en particulier une composition dermatologique destinée au traitement de l'acné et/ou de l'érythème fessier.
PCT/DK2014/050265 2013-09-02 2014-09-01 Composition dermatologique WO2015028035A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14776569.7A EP3041460A1 (fr) 2013-09-02 2014-09-01 Composition dermatologique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201370488 2013-09-02
DKPA201370488 2013-09-02

Publications (1)

Publication Number Publication Date
WO2015028035A1 true WO2015028035A1 (fr) 2015-03-05

Family

ID=51625754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2014/050265 WO2015028035A1 (fr) 2013-09-02 2014-09-01 Composition dermatologique

Country Status (2)

Country Link
EP (1) EP3041460A1 (fr)
WO (1) WO2015028035A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109010248A (zh) * 2018-10-30 2018-12-18 广州市尚昇生物科技有限公司 一种香薰喷雾及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1085735A (fr) * 1976-10-15 1980-09-16 Francis E.J. Oneto Compose contre l'acne contenant un lactate d'alkyle et de l'alkylene glycol
FR2759910A1 (fr) * 1997-02-24 1998-08-28 Greentech Sa Compositions cosmetiques ou dermopharmaceutiques pour le raffermissement du buste, la stimulation du systeme capillaire et l'inhibition ou systeme pileux, contenant des extraits de kigelia africana
DE10200490A1 (de) * 2002-01-04 2003-07-10 Knoell Hans Forschung Ev Verwendung von Formulierungen, die Teile der Pflanze Kigelia africana enthalten
WO2006002443A1 (fr) * 2004-06-24 2006-01-05 Rudolf Karl Schleipfer Preparation pharmaceutique ou cosmetique a base de kigelia africana

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1085735A (fr) * 1976-10-15 1980-09-16 Francis E.J. Oneto Compose contre l'acne contenant un lactate d'alkyle et de l'alkylene glycol
FR2759910A1 (fr) * 1997-02-24 1998-08-28 Greentech Sa Compositions cosmetiques ou dermopharmaceutiques pour le raffermissement du buste, la stimulation du systeme capillaire et l'inhibition ou systeme pileux, contenant des extraits de kigelia africana
DE10200490A1 (de) * 2002-01-04 2003-07-10 Knoell Hans Forschung Ev Verwendung von Formulierungen, die Teile der Pflanze Kigelia africana enthalten
WO2006002443A1 (fr) * 2004-06-24 2006-01-05 Rudolf Karl Schleipfer Preparation pharmaceutique ou cosmetique a base de kigelia africana

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GNPD [online] MINTEL; April 2012 (2012-04-01), "Total Body Slimming Toning Gel", XP002732881, Database accession no. 1766823 *
GRACE O M ET AL: "ANTIBACTERIAL ACTIVITY AND ISOLATION OF ACTIVE COMPOUNDS FROM FRUIT OF THE TRADITIONAL AFRICAN MEDICINAL TREE KIGELIA AFRICANA", SOUTH AFRICAN JOURNAL OF BOTANY - SUID-AFRIKAANS TYDSKRIFT VIRPLANTKUNDE, FOUNDATION FOR EDUCATION, SCIENCE AND TECHNOLOGY, PRETORIA, SA, vol. 68, no. 2, 1 July 2002 (2002-07-01), pages 220 - 222, XP009056513, ISSN: 0254-6299 *
OMONKHELIN J OWOLABI ET AL: "Antifungal and antibacterial activities of the ethanolic and aqueous extract of Kigelia africana (Bignoniaceae) stem bark", AFRICAN JOURNAL OF BIOTECHNOLOGY, vol. 6, 18 July 2007 (2007-07-18), pages 1677 - 1680, XP055154533 *
PROTTEY C ET AL: "THE MODE OF ACTION OF ETHYL LACTATE AS A TREATMENT FOR ACNE", BRITISH JOURNAL OF DERMATOLOGY, OXFORD : WILEY-BLACKWELL, UK, vol. 110, 1 January 1984 (1984-01-01), pages 475 - 485, XP001056245, ISSN: 0007-0963, DOI: 10.1111/J.1365-2133.1984.TB04663.X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109010248A (zh) * 2018-10-30 2018-12-18 广州市尚昇生物科技有限公司 一种香薰喷雾及其制备方法
CN109010248B (zh) * 2018-10-30 2021-05-14 广州市尚昇生物科技有限公司 一种香薰喷雾及其制备方法

Also Published As

Publication number Publication date
EP3041460A1 (fr) 2016-07-13

Similar Documents

Publication Publication Date Title
Mohiuddin Skin care creams: formulation and use
Lodén Effect of moisturizers on epidermal barrier function
US8691298B2 (en) Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care
TWI287995B (en) Dermatological composition containing co-enzyme Q as active ingredient
KR20190101948A (ko) 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
CN107753332B (zh) 一种多效油膏
WO2012015487A1 (fr) Combinaison de dapsone avec de l'adapalène
EP3482742A1 (fr) Composition moussante pour la peau
KR20060020630A (ko) 피지 관련 피부 질환의 국소 치료방법
TW201605444A (zh) 包含奧替尼啶二鹽酸鹽之局部醫藥組成物或化妝品組成物
JP2008503558A (ja) 局所治療用組成物
WO2011138364A1 (fr) Composition topique et son utilisation pour la prophylaxie et le traitement de défauts liés à des dermatoses inflammatoires
US9011943B2 (en) Compositions and methods for alleviating skin disorders
WO2015028035A1 (fr) Composition dermatologique
US20200030398A1 (en) Skin care composition
JP2007332055A (ja) 皮膚外用剤
KR20050048287A (ko) 아토피성 피부염을 개선을 위한 화장품 조성물
AU2007200216A1 (en) Skin formulation usable as a therapeutic application for the treatment of general skin disorders and a method of preparation thereof
ES2653787B1 (es) Composiciones de ácido cromoglícico para el tratamiento de la dermatitis
EP3074005A2 (fr) Composition pour le traitement d'une dermatite
EP4052763A1 (fr) Formulation pour application externe et son utilisation
Dewi et al. The Comparison of the Effects of Caffeine Topical 0.25% and 0.5% as Anti-wrinkle Therapy
US20190060260A1 (en) N-bromotaurine solutions and emulsions against abnormal cells
RU2489144C2 (ru) Фармацевтическая композиция для лечения заболеваний кожи и способ ее получения
KR20240137862A (ko) 제니스테인을 함유하는 여드름 예방 및 치료용 화장료

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14776569

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2014776569

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014776569

Country of ref document: EP